Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
244 studies found for:    Thrombocytopenia: Clinical Trials
Show Display Options
Rank Status Study
21 Terminated High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
Conditions: Infant, Premature;   Erythropoietin;   Brain Injury;   Intraventricular Hemorrhage;   Periventricular Leukomalacia;   Neurodevelopmental Outcomes;   Randomized Clinical Trial
Interventions: Drug: Erythropoietin;   Drug: Saline placebo
22 Completed
Has Results
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Condition: Hepatitis C
Interventions: Drug: Eltrombopag;   Drug: Antiviral therapy
23 Active, not recruiting Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
Conditions: Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: Placebo;   Drug: Eltrombopag
24 Recruiting Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion
Conditions: Blood Platelet Transfusion;   Blood Clotting
Intervention: Drug: Administration of platelet concentrate and taking blood samples
25 Unknown  Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Romiplostim
26 Completed
Has Results
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Drug: Ofatumumab 500mg;   Drug: Ofatumumab 1000mg;   Drug: Fludarabine;   Drug: Cyclophosphamide
27 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
28 Not yet recruiting Milk-only Lactation Study for Patients on Eltrombopag
Condition: Thrombocytopaenia
Intervention: Drug: eltrombopag
29 Not yet recruiting Observational Trial of a Therapeutic Platelet Transfusion Regimen
Conditions: Acute Myeloid Leukemia;   Thrombocytopenia
Intervention:
30 Recruiting A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Condition: Leukaemia, Acute
Interventions: Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Eltrombopag;   Drug: Placebo
31 Completed
Has Results
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Carboplatin;   Drug: Paclitaxel
32 Unknown  High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Conventional-dose prednisone group;   Drug: High-dose dexamethasone group
33 Enrolling by invitation A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer
Condition: Gynecologic Cancer
Interventions: Drug: Eltrombopag;   Drug: Placebo
34 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
35 Completed PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
Conditions: Venous Thromboembolism;   Postpartum
Intervention: Drug: Dalteparin Sodium
36 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Conditions: Critical Illness;   Deep Venous Thrombosis
Interventions: Drug: LMWH (Fragmin, dalteparin);   Drug: Unfractionated Heparin
37 Recruiting A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag Tablets;   Drug: Eltrombopag PfOS
38 Recruiting Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Condition: Antiphospholipid (aPL)-Positive
Intervention: Biological: Study Drug- ALXN1007
39 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
Conditions: Critically Ill;   Deep Venous Thrombosis
Intervention: Drug: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)
40 Terminated
Has Results
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
Conditions: Brain and Central Nervous System Tumors;   Drug/Agent Toxicity by Tissue/Organ;   Lymphoma;   Thrombocytopenia
Interventions: Drug: Rituxan;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Cytarabine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years